SPOTLIGHT -
Newly Defined Breast Cancer Targets Expand TNBC Treatment Options
FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
State of Science Summit- Breast Cancers: Chaired by Stephanie Graff, MD, FACP
Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer
Integrating New Standards for Metastatic HER2+ Breast Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
